Telemedicine home CPAP titration and follow-up in the COVID-19 scenario

Jaume Bordas-Martinez, Neus Salord, Eva Fontanilles, Eliseo Prado, María Calvo, João Carmezim, Salud Santos, Carmen Monasterio

Please cite this article as: Bordas-Martinez J, Salord N, Fontanilles E, et al. Telemedicine home CPAP titration and follow-up in the COVID-19 scenario. ERJ Open Res 2022; in press (https://doi.org/10.1183/23120541.00084-2022).

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.

Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Telemedicine home CPAP titration and follow-up in the COVID-19 scenario

Take Home Message: Telemedicine home CPAP titration and early follow-up is equivalent to usual care in adaption and compliance while achieving greater patient satisfaction. The use of a mHealth app may help patients self-empower and encourage increased CPAP use.

+ Jaume Bordas-Martinez¹, Neus Salord¹, Eva Fontanilles¹, Eliseo Prado¹, María Calvo¹, João Carmezim², Salud Santos¹, * Carmen Monasterio¹

1. Respiratory Department. Bellvitge University Hospital. IDIBELL. University of Barcelona. Hospitalet de Llobregat (Barcelona), Spain.
2. Biostatistics Unit, Institut Investigacions Biomèdiques de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

+ First author
* Corresponding author

* Corresponding author
Carmen Monasterio Ponsa, MD, PhD
Head of the Sleep Unit. Respiratory Dpt.
University Hospital of Bellvitge. IDIBELL
Hospitalet de Llobregat, 08907 (Barcelona)
cmonasterio@bellvitgehospital.cat
Tel. number: 0034 932607689
Barcelona, February 15th 2022

Keywords: OSA, CPAP, titration, COVID-19, telemedicine, telemonitoring, smartphone, mHealth, cost, patient satisfaction
INTRODUCTION

Obstructive sleep apnea (OSA) is a highly prevalent chronic disease associated with important comorbidities such as traffic accidents, cardiovascular and metabolic diseases and mortality, among others (1). Continuous positive airway pressure (CPAP), a first-line therapy in moderate-severe OSA (2), has been proven successful in improving daytime sleepiness, quality of life, reducing traffic accidents (3), improving hypertension and paroxistial atrial fibrillation (4,5). However, 47% of successfully titrated patients abandon treatment within three years (5,6). Thus, early OSA and CPAP education with close follow-up is mandatory to achieve satisfactory CPAP compliance (6,7). In that context, telemedicine and telemonitoring through remote monitoring CPAP have become promising strategies (8,9). Recently, smartphone applications (10) and wearables (11) have been added as new suggested tools for improving CPAP compliance.

The onset of the coronavirus disease 2019 (COVID-19) pandemic (12) saw a reduction in sleep unit activity of almost 80% in the two first months (13). As SARS-COV-2 remains viable in aerosols for three hours (14), CPAP titration is a challenging procedure as it generates droplet dispersion and involves a noteworthy increase of the biological risk for both medical staff and patients. Hence, home strategies for respiratory therapies with the implementation of telemedecine were encouraged by medical societies to diminish the risk of COVID-19 infection (15,16). Previous studies, have shown satisfactory results in CPAP home titration (17) and CPAP follow-up by telemedicine (18). The feasibility of smartphone applications, as well as the so-called mHealth app (10,19,20), has also been demonstrated. Nevertheless, to our best knowledge, there is no study on CPAP titration by telemedicine in the new COVID-19 scenario comparing different telemedicine strategies including telemonitoring with and without a smartphone application for clinical CPAP follow-up.

Therefore, this study aims to compare telemedicine strategies for home CPAP titration initiated in the COVID-19 pandemic scenario with the previous standard CPAP home titration through hospital face-to-face visits.

METHODS

Study design

A prospective telemedicine cohort (TC) undergoing CPAP titration and follow-up initiated to restart titrations during the COVID-19 pandemic scenario was compared with a retrospective cohort (RC) with the usual CPAP home titration and follow-up. The TC included a subgroup using a smartphone application (TC-APP).

The main endpoints were successful CPAP adaptation and CPAP compliance at one month of follow-up. Secondary endpoints were reported patient satisfaction and the direct staff costs of the different telemedicine approaches.

This study was approved by the ethics committee at our tertiary care level hospital (PR271/20). The telemedicine prospective included patient signed informed consent, whereas for the retrospective patient oral informed consent was obtained via a telephone call and then registered in the clinical records.

Patients

Patients were consecutively recruited for both cohorts from February to May 2019 for RC and from September 2020 to February 2021 for TC.

Eligible patients were adults (≥ 18 years old) with a recent OSA diagnosis and CPAP treatment indication. Patients under CPAP treatment, or unstable acute or chronic diseases were excluded. A certain educational level or regular smartphone use was not required for inclusion. At baseline, all clinical, demographic and sleep variables were registered for the two cohorts.
Home CPAP titration strategies

The home-CPAP titration workflow in the RC was initiated by scheduling an in-person visit in the hospital by a sleep unit nurse, who provided educational information with additional written support, performed individual CPAP training for 45-60 minutes and selected an appropriate mask. Then, autoCPAP was delivered to the patient, who returned it the next day and after the data was downloaded, a fixed pressure was prescribed. The optimal pressure was determined visually on the raw data as the pressure that covered 90% of the period without leaks (17). The titration was considered unsuccessful when sleep time was subjectively under five hours or when significant leaks were observed during most of the night. The home titration procedure was repeated up to two additional times when the home CPAP titration circuit was considered unsuccessful. Those patients were excluded from further analysis in this study and in-laboratory full polysomnographic CPAP titration was performed. After a successful titration, the CPAP was supplied to patient by the healthcare provider, and the sleep unit nurse phone number was given to the patient to use in case of requiring assistance. Face-to-face follow-up at one month by a sleep unit nurse was performed assessing CPAP compliance and adverse effects. Patient satisfaction was obtained by phone specifically for the study at inclusion.

The two TC strategies implemented were: 1) Nurse call-visit informing about CPAP titration procedure. Information was also sent by both postal letter and email. Information included an educational YouTube video link regarding CPAP use and training. Additionally, the phone number of the sleep unit nurse was given to the patient in case of requiring assistance. The healthcare provider supplied autoCPAP (Dreamstation CPAP Pro, Respironics) for three nights (pressure range: 6-12 cmH2O), which was equipped with a modem for remote data transmission and titration. The sleep unit nurse telemonitored CPAP compliance, leaks, residual IAH and pressure through the EncoreAnywhere platform and a phone call or videoconference visit was performed if required. A CPAP fixed pressure was prescribed as described previously according to the three-night raw data (17). The healthcare provider supplied the CPAP device. Cases of unsuccessful home titration were referred to in-laboratory titration (and were also excluded from further analysis, as in the RC). A phone call or videoconference follow-up sleep unit nurse visit was performed at one month to assess adverse effects, patient satisfaction and objective CPAP adherence as registered by the home CPAP device used by the patient was obtained by the health care provider) The second telemedicine strategy also included recommending the use of a smartphone application (Estoi®), a download link and written information were sent by letter and email.

Estoi® is a smartphone application that provides: 1) educational information in text and video formats regarding CPAP use and frequent adverse effects or problems; 2) side effects, tolerance and compliance questionnaires with weekly reminder notifications; 3) an algorithm that recommends educational texts and videos based on the problems detected in the questionnaires; 4) telemonitoring of questionnaires by the medical team with an alarm system; and 5) open messaging system between the patient and medical team.

Statistics

Demographic, clinical, OSA treatment, and titration variables were analyzed according to the type of variable and are presented in tables according to the study group. The raw effect of the group on these variables was analyzed using logistic regression models. The model was replicated by adding variables such as age, sex, body mass index (BMI), educational level, and apnea to observe the adjusted effect. The raw effect of the group on these variables was analyzed using linear models according to the distribution of the variable. To observe the adjusted effect, the model was replicated by adding variables such as age, sex, BMI, educational level, and apnea. Staff direct cost were estimated using €32.76/hour for the specialized sleep nurse and €52.92/hour for the sleep doctor.

RESULTS
210 consecutive patients were evaluated (80 RC and 130 TC). Nine were excluded in the RC and 13 in the TC (Figure 1). From 188 analyzed patients, 71 were RC and 117 were TC of which 44 patients were not offered the app, and 76 were offered the app, which was used by 36 patients (TC-APP).

Patients’ characteristics are shown in Table 1. No significant baseline differences were detected between the retrospective and telemedicine cohorts, neither between those who used the app and those who did not. Sleep study and OSA characteristics are depicted in Table 2, no relevant differences were found between the RC and TC. Baseline IAH was higher in TC-app vs TC-noAPP (IAH 53.1/h versus 36.8/h respectively, p=0.022).

CPAP was successfully titrated and adapted in 90% of the RC, while for TC the corresponding figure was 94.9% and 100% in TC-APP. Despite the improvement in the TC, and especially in TC-APP, the differences did not reach statistical significance. However, successful single-time CPAP titration was significantly higher (p<0.001) in the TC (99%) than in the RC (78.9%). Attendance at the first follow-up visit was significantly higher in the TC than in the RC (100% vs 90%, p=0.0044).

No CPAP compliance differences were found between cohorts. When assessing the RC versus TC by multivariate logistic models, age was the only factor which increased by 5% the probability of one month CPAP compliance > four hours per night (Odds Ratio [OR] 1.05, Confidential Interval [CI] 1.02-1.09, p=0.002) (Table 3; A). Whereas in the two TC (with and without APP) multivariate logistic models, a high educational level increased the probability of one month CPAP compliance > 4hours per night by 294% (OR 3.94, CI 1.33-13.04, p-value 0.017) (Table 3; B).

Patient satisfaction (0-10) was significatively higher (p<0.001) in the TC (9.02/10 (SD 0.64)) than in the RC (7.69/10 (2.05 SD)), and 68.9% of RC patients were satisfied vs. 98% TC, p-value <0.001 according to the survey of patients (Table 4). Patient satisfaction remained significatively higher in TC when adjusted for other important parameters (see Table 3,C). Patients in the TC reported easier access to healthcare staff compared to patients in the RC (100% vs. 59%, p-value <0.001). Thirty-six percent of the patients in the RC would prefer a new CPAP adaptation to be performed telematically, while 94% of the TC would have preferred a new telematic process (p-value <0.001). Finally, our telemedicine strategy would be recommended to others by 96% of the patients. Non-significant differences were detected in satisfaction between both telemedicine strategies. Nevertheless, 64% of the TC-APP reported that their telemedicine strategy influenced in increase in CPAP use compared to 45% in the TC-noAPP (p-value 0.011).

Regarding the patients in the TC-APP (Table 5), 66% responded to the app questionnaires, 61% used the messaging system, 73% of the messages were initiated by the patient and 27% by the medical team because of an alarm in the system. Nine messages sent via APP (43%) resulted in an action to improve CPAP adaptation. The compliance reported by the app was, on average, 6.36 hours per night (SD 1.21), which did not correlate with objective CPAP compliance hours (r 0.58).

CPAP adaptation with follow-up had an estimated staff direct cost per patient of €19.61 (SD 8.61) in TC-noAPP compared to €23.79 (SD 9.94) in TC-APP (p-value 0.0483).

**DISCUSSION**

To the best of our knowledge, this is the first CPAP titration and follow-up study performed entirely during the COVID-19 pandemic through two different telemedicine strategies which are compared with the face-to-face standard of care in place before the pandemic. Our main results showed that telemedicine is equivalent to the previous standard care in terms of successful titration and in CPAP compliance at one month of follow-up, as well as providing higher patient satisfaction. The additional use of the app can facilitate compliance in the patients’ opinion, but no significant differences were demonstrated in this group.
The new COVID-19 scenario has presented unsuspected challenges and has advanced telemedicine implementation (13) responding to concerns of biological risk (14), especially in respiratory care units (15,16). The new strategies developed to maintain activity in the sleep units have been achievable as a result of previous experience in telemedicine (21–23), and, more than a temporary solution, they could represent an option to be considered in regular activity.

Our data showed that successful CPAP adaptation and titration increased in TC (95%), especially in TC-APP (100%), against RC (90%), without achieving statistical significance, probably due to the small sample size. This telemonitored titration protocol based on sleeping several nights at home with the autoCPAP device takes advantage of not requiring additional patient displacement, since adherence, air leakage and pressure are remotely managed, and daily sleep unit staff intervention can improve adaptation in consecutive days, increasing successful CPAP titration.

One month CPAP compliance and sleepiness measured by Epworth sleepiness score was similar in the RC and TC. Therefore, the telemedicine strategy used is as useful as face-to-face management, not only for achieving CPAP titrations, but also for achieving good compliance and clinical response at one-month of follow-up, which is a predictor of good long-term CPAP compliance (24). Likewise, in the multivariate analysis, neither RC nor TC, nor gender, basal AIH, BMI, or Epworth had an influence on compliance > 4 h of CPAP/night. Only age was related to greater compliance. Therefore, this supports the idea of not limiting the use of titration by telemedicine in older patients.

Studies analyzing different telemedicine strategies for CPAP follow-up have found that CPAP compliance was equivalent to that with usual care (18,25–28). Only a few studies were successful in increasing CPAP compliance up to 30 min/night through phone coaching implementation (26 min/night) (29), or other methods .Nevertheless, a recent CPAP telemonitoring meta-analysis (22) did not find differences in CPAP compliance with telemonitored and standard CPAP follow-up. In our study, it is worth noting that a sleep unit telephone number was already available to patients in our standard care system previous to COVID-19, so there was no improvement in TC in terms of adaptation or during follow-up.

Only one other study carried out during the COVID-19 pandemic (30) has evaluated the telemedicine approach of CPAP titration compared with face-to-face titration. Similar to this study, equivalence in one month CPAP compliance was observed. Nevertheless, CPAP telemonitoring was performed throughout the entire study period (30), whereas in the present study, telemonitoring was only performed during the three days of CPAP titration. The equipment used after titration was chosen because of CPAP provider availabilities. Nevertheless, the present study demonstrated that telemonitoring titration plus standard CPAP after titration and telematic follow-up obtains equivalent results as in-person titration and contributes to building up new evidence supporting alternative telematic titration workflows.

Regarding perceived patient satisfaction, the TC reported greater satisfaction than RC. The patients probably perceived as a significant advantage avoiding displacement to the hospital during the pandemic. Moreover, one of the most promising reported telemedicine benefits was patient satisfaction, and especially when the mHealth app was incorporated. Using the “APPnea” smartphone application for CPAP self-monitoring Iseta et al (18), found that 83% of patients were very satisfied compared to 72% in the control group and 82% of patients would integrate as part of follow-up. The latest study (20) using “APPnea” for recovering patients with poor adherence to CPAP was reported useful by 60% of patients, while 82% would recommend the app to other patients and 85% would integrate it as part of follow-up. Similarly, our patient's satisfaction was significantly greater in the TC with a mean value of 9.02/10 (0.64 SD) against RC 7.69/10 (2.05 SD) (p-value <0.001). In addition, only 6% of the patients in the TC reported that would prefer to perform it face-to-face. Interestingly, 36% of our RC would prefer to perform teleatically, and 96% of TC recommend our telemedicine program to others. Patients in both telemedicine strategies reported easy access to healthcare professionals, felt confident about the security of their confidential data and would recommend the telemedicine strategy used to others. The loss of the human patient-doctor relationship is the greatest risk of
telemedicine use (21,23); however, these studies show the potential of bringing the patient closer to the doctor when the technology is used appropriately.

Unlike other sleep telemedicine studies which used mobile applications (20,31), in our methodological design, patients without technological skills were not excluded. Even though the percentage of patients who used the mobile application was not high (33/76), there were no differences in the educational level or age among those who used the app and those who did not. This fact contrasts with the well-known barriers to adopting telemedicine (32), such as resistance to change, cost, elderly age and educational level. The COVID-19 pandemic may have influenced in decreasing telemedicine barriers by reducing resistance to change from elderly people when technological use became essential for staying in contact with their relatives, avoiding social isolation and loneliness (33). Nevertheless, the influence of educational level on CPAP compliance observed in telemedicine multivariable models suggests that it is more important than telemedicine itself. Patients who used the application and asked questions about side effects had their questions answered before the one-month visit (43% of the questions generated an action to improve CPAP adaptation, mostly change of mask). Moreover, most patients in the TC-APP reported that telemedicine influenced in increasing CPAP use, though overall, no increase in compliance was found compared to TC-noAPP.

The other outstanding benefit of telemedicine is cost-efficiency. Previous studies demonstrated that telemedicine strategies for follow-up (without titration involvement) were cost-efficient: Isetta et al (18) reported a cost of €168.4 for web site follow-up in a telemedicine group compared to €180.4 for the control group, while Garmendia et al (20) estimated a cost of €103 per-protocol patient, reaching €152 for patients recovered in a rescue study of low CPAP compliance patients. We estimated only the direct medical staff time cost in the TC and the cost was only slightly higher in the TC-APP group. This cost is very small and could be cost-effective if better compliance is demonstrated in further studies.

This study has several limitations, beginning with a retrospective control group and an unrandomized design. Nevertheless, these factors could also be considered a strength since it allowed us to compare our TC findings with real-life retrospective usual care previous to the COVID-19 pandemic. Patient satisfaction questionnaires were obtained by phone which may constitute a bias per se as this method precludes anonymity. Furthermore, for the RC, they were completed after one year, which may have altered the results compared to the one-month evaluation. There was no bias in prospective or prospective cohorts, all consecutive patients were included, as no differences were found between groups. This ensures that the results are reproducible in routine clinical practice. Patient self-selection in the use of the mobile application would be another limitation. However, it is also an opportunity to evaluate two different telemedicine strategies including app use, in contrast with other telemedicine studies that excluded patients without technological abilities. Finally, the cost analysis only includes direct staff cost using the rates provided by the accounting department of a hospital in the Spanish public healthcare system, and therefore cannot be extrapolated in absolute terms to private centers or to other countries. However, the cost analysis does serve to illustrate the small relative difference between the two strategies.

**CONCLUSIONS**

Telemedicine for CPAP adaptation and titration and early follow-up are equivalent to usual care face-to-face visits in terms of successful CPAP titration and compliance, with greater patient satisfaction, and it can therefore be used independently of the COVID-19 pandemic. The use of the mHealth app could help patients to self-empower, as well as encouraging them to increase CPAP use. However, further studies are needed to confirm its value.

**Funding**: The authors report no involvement in the research by the sponsor that could have influenced the outcome of this work.
Acknowledgements: The authors wish to thank LINDE Healthcare Spain for their support providing AutoCPAP devices, Jordi Sanchez for the free of charge use of the Estoi® app. and David Bridgewater for the English revision of the manuscript.

Conflict of interests: Jaume Bordas-Martinez participated in the development of the smartphone application. However, this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

1. Mediano O, González Mangado N, Montserrat JM, et al. Documento internacional de consenso sobre apnea obstructiva del sueño. Arch Bronconeumol 2021;81:e89–92.
2. Patil SP, Ayappa IA, Caples SM, et al. Treatment of adult obstructive sleep apnea with positive airway pressure: An American academy of sleep medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med 2019;15:301–34.
3. Karimi M, Hedner J, Häbel H, et al. Sleep apnea related risk of motor vehicle accidents is reduced by continuous positive airway pressure: Swedish traffic accident registry data. Sleep 2015;38:341–9.
4. Javaheri S, Martinez-Garcia MA, Campos-Rodriguez F, et al. Continuous positive airway pressure adherence for prevention of major adverse cerebrovascular and cardiovascular events in obstructive sleep apnea. Am J Respir Crit Care Med 2020;201:607–10.
5. Pépin JL, Bailly S, Rinder P, et al. Cpap therapy termination rates by osa phenotype: A French nationwide database analysis. J Clin Med 2021;10:1–10.
6. Catchesda PG. Predictors of continuous positive airway pressure adherence. F1000 Med Rep 2010;2:1–6.
7. Babbin SF, Velicer WF, Aloia MS, et al. Identifying Longitudinal Patterns for Individuals and Subgroups: An Example with Adherence to Treatment for Obstructive Sleep Apnea. Multivariate Behav Res 2015;50:91–108.
8. Hwang D, Chang JW, Benjafield A V., et al. Effect of Telemedicine Education and Telemonitoring on Continuous Positive Airway Pressure Adherence. The Tele-OSA Randomized Trial. Am J Respir Crit Care Med 2018;197:117–26.
9. Murase K, Tanizawa K, Minami T, et al. A randomized controlled trial of telemedicine for long-term sleep apnea continuous positive airway pressure management. Ann Am Thorac Soc 2020;17:329–37.
10. Suárez-Giron M, Garmendia O, Lugo V, et al. Mobile health application to support CPAP therapy in obstructive sleep apnoea: design, feasibility and perspectives. ERJ Open Res 2020;6:00220–2019.
11. Guillodo E, Lemey C, Simonnet M, et al. Clinical applications of mobile health wearable–based sleep monitoring: Systematic review. JMIR MHealth UHealth 2020;8.
12. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
13. Grote L, McNicholas WT, Hedner J, et al. Sleep apnoea management in Europe during the COVID-19 pandemic – Data from the European Sleep Apnoea Database (ESADA). Eur Respir J 2020;55:2–6.
14. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020;382:1564–7.
15. Schiza S, Simonds A, Randerath W, et al. Sleep laboratories reopening and COVID-19: A European perspective. Eur Respir J 2021;57.
16. Montserrat Canal JM, Suárez-Girón M, Egea C, et al. Posicionamiento de la Sociedad Española de Neumología y Cirugía Torácica en el uso de la telemedicina en los trastornos respiratorios del sueño y ventilación mecánica. Arch Bronconeumol 2021;57:281–90.
17. Masa JF, Jiménez A, Durán J, et al. Alternative Methods of Titrating Continuous Positive Airway Pressure. Am J Respir Crit Care Med 2004;170:1218–24.
18. Issetta V, Negrín MA, Monasterio C, et al. A Bayesian cost-effectiveness analysis of a telemedicine-based strategy for the management of sleep apnoea: A multicentre randomised controlled trial. Thorax 2015;70:1054–61.
19. Issetta V, Torres M, González K, et al. A New mHealth application to support treatment of sleep apnoea patients. J Telemed Telecare 2017;23:14–8.
20. Garmendia O, Farré R, Ruiz C, et al. Telemedicine Strategy to Rescue CPAP Therapy in Sleep Apnea Patients with Low Treatment Adherence: A Pilot Study. J Clin Med 2021;10:4123.
21. Aardoom JJ, Loheide-Niesmann L, Osseaarda HC, et al. Effectiveness of Electronic Health
Interventions in Improving Treatment Adherence for Adults With Obstructive Sleep Apnea: Meta-Analytic Review. J Med Internet Res 2020;22:e16972.

22. Chen C, Wang J, Pang L, et al. Telemonitor care helps CPAP compliance in patients with obstructive sleep apnea: a systemic review and meta-analysis of randomized controlled trials. Ther Adv Chronic Dis 2020;11:204062232090162.

23. Hu Y, Su Y, Hu S, et al. Effects of telemedicine interventions in improving continuous positive airway pressure adherence in patients with obstructive sleep apnoea: a meta-analysis of randomised controlled trials. Sleep Breath 2021;25:1761–71.

24. Van Ryswyk E, Anderson OS, Antic NA, et al. Predictors of long-term adherence to continuous positive airway pressure in patients with obstructive sleep apnea and cardiovascular disease. Sleep 2019;42:1–9.

25. Contal O, Poncin W, Vaudan S, et al. One-Year Adherence to Continuous Positive Airway Pressure With Telemonitoring in Sleep Apnea Hypopnea Syndrome: A Randomized Controlled Trial. Front Med 2021;8:1–7.

26. Tamisier R, Treptow E, Joyeux-Faure M, et al. Impact of a Multimodal Telemonitoring Intervention on CPAP Adherence in Symptomatic OSA and Low Cardiovascular Risk: A Randomized Controlled Trial. Chest 2020;158:2136–45.

27. Schoch OD, Baty F, Boesch M, et al. Telemedicine for Continuous Positive Airway Pressure in Sleep Apnea. A Randomized, Controlled Study. Ann Am Thorac Soc 2019;16:1550–7.

28. Koolj L, Vos PJE, Dijkstra A, et al. Video Consultation as an Adequate Alternative to Face-to-Face Consultation in Continuous Positive Airway Pressure Use for Newly Diagnosed Patients With Obstructive Sleep Apnea: Randomized Controlled Trial. JMIR Form Res 2021;5:e20779.

29. Sedkaoui K, Leesux L, Pontier S, et al. Efficiency of a phone coaching program on adherence to continuous positive airway pressure in sleep apnea hypopnea syndrome: A randomized trial. BMC Pulm Med 2015;15:1–8.

30. Garmendia O, Monasterio C, Guzmán J, et al. Telemedicine Strategy for CPAP Titration and Early Follow-up for Sleep Apnea During COVID-19 and Post-Pandemic Future. Arch Bronconeumol 2021;57:56–8.

31. Isetta V, Torres M, González K, et al. A New mHealth application to support treatment of sleep apnoea patients. J Telemed Telecare 2017;23:14–8.

32. Scott Kruse C, Karem P, Shifflett K, et al. Evaluating barriers to adopting telemedicine worldwide: A systematic review. J Telemed Telecare 2018;24:4–12.

33. Noone C, McSharry J, Smalle M, et al. Video calls for reducing social isolation and loneliness in older people: a rapid review. Cochrane Database Syst Rev 2020;2020:1–40.
|                                    | Retrospective cohort (RC) vs Telemedicine cohort (TC) | TC: Smartphone application not used vs Used |
|------------------------------------|------------------------------------------------------|---------------------------------------------|
|                                    | RC | TC | p.value | TC_noAPP | TC_APP | p.value |
| Gender (Male), N (%):              | 48 (67.6%) | 80 (68.4%) | 1.000 | 57 (70.4%) | 23 (63.9%) | 0.631 |
| Age, Mean (Standard Deviation)     | 57.8 (11.6) | 59.5 (12.6) | 0.338 | 60.6 (12.9) | 57.1 (11.6) | 0.142 |
| Smoking exposure, N (%):           | 25 (35.2%) | 51 (43.6%) | 0.093 | 34 (42.0%) | 17 (47.2%) | 0.131 |
| Never                              | 17 (23.9%) | 36 (30.8%) | 0.631 | 22 (27.2%) | 14 (38.9%) | 0.629 |
| Former smoker                      | 29 (40.8%) | 30 (25.6%) | 0.629 | 25 (30.9%) | 5 (13.9%) | 0.629 |
| BMI, Mean (Standard Deviation)     | 36.6 (9.63) | 34.8 (7.21) | 0.181 | 34.9 (7.05) | 34.7 (7.66) | 0.884 |
| BMI categories, N (%):             | 2 (2.82%) | 7 (5.98%) | 0.250 | 3 (3.70%) | 4 (11.1%) | 0.239 |
| Normal or healthy Weight           | 18 (25.4%) | 19 (16.2%) | 0.250 | 15 (18.5%) | 4 (11.1%) | 0.250 |
| Obese                              | 51 (71.8%) | 91 (77.8%) | 0.629 | 63 (77.8%) | 28 (77.8%) | 0.629 |
| Arterial hypertension, N (%)       | 44 (62.0%) | 67 (57.3%) | 0.459 | 48 (59.3%) | 19 (52.8%) | 0.652 |
| Diabetes mellitus, N (%)           | 16 (22.5%) | 25 (21.4%) | 0.459 | 18 (22.2%) | 7 (19.4%) | 0.925 |
| Dyslipidemia, N (%)                | 32 (45.1%) | 45 (38.5%) | 0.459 | 32 (39.5%) | 13 (36.1%) | 0.887 |
| Gastro-oesophageal reflux disease  | 4 (5.63%) | 2 (1.71%) | 0.201 | 1 (1.23%) | 1 (2.78%) | 0.523 |
| Kidney disease                     | 5 (7.04%) | 4 (3.42%) | 0.201 | 3 (3.70%) | 1 (2.78%) | 1.000 |
| Heart disease, N (%)               | 18 (25.4%) | 18 (15.4%) | 0.136 | 13 (16.0%) | 5 (13.9%) | 0.983 |
| Respiratory disease, N (%):        | 2 (2.82%) | 7 (5.98%) | 1.000 | 7 (8.64%) | 3 (8.33%) | 1.000 |
| COPD                               | 6 (8.45%) | 2 (1.71%) | 1.000 | 2 (2.47%) | 0 (0.00%) | 1.000 |
| Asthma                             | 2 (2.82%) | 0 (0.00%) | 1.000 | 0 (0.00%) | 0 (0.00%) | 1.000 |
| Interstitial Lung Disease          | 6 (8.45%) | 9 (7.69%) | 1.000 | 8 (9.88%) | 1 (2.78%) | 0.271 |
| Neurological disease, N (%)        | 5 (7.04%) | 4 (3.42%) | 0.299 | 3 (3.70%) | 1 (2.78%) | 1.000 |
| Hypothyroidism                     | 4 (5.63%) | 3 (2.56%) | 0.299 | 1 (1.23%) | 2 (5.66%) | 0.242 |
| Migraine                           | 0 (0.00%) | 4 (3.42%) | 0.299 | 3 (3.70%) | 1 (2.78%) | 0.242 |
| Fibromyalgia                       | 1 (1.41%) | 3 (2.56%) | 0.299 | 2 (2.47%) | 1 (2.78%) | 1.000 |
| Depression/anxiety                 | 7 (9.86%) | 17 (14.5%) | 0.481 | 14 (17.3%) | 3 (8.33%) | 0.325 |
| Malignant disease history          | 5 (7.04%) | 2 (1.71%) | 0.106 | 2 (2.47%) | 0 (0.00%) | 1.000 |
| Educational level, N (%):          | 0.175 | 0.175 | 1.000 | 0.175 | 0.175 | 1.000 |
| Reading and writing difficulties OR No High School | 40 (58.0%) | 78 (69.0%) | 0.175 | 56 (71.8%) | 22 (62.9%) | 0.465 |
| High School and Associated degree OR College and Graduate degree | 29 (42.0%) | 35 (31.0%) | 0.175 | 22 (28.2%) | 13 (37.1%) | 1.000 |
| Table 2. OSA diagnosis, CPAP treatment and follow-up |
|--------------------------------------------------|
| **OSA DIAGNOSIS**                                |
| Diagnosis OSA study test, N (%):                  |
| Noctaln pulsoximetry                            |
| 1 (1.41%)                                       |
| Respiratory polygraphy                          |
| 44 (62.0%)                                      |
| Polysomnography                                 |
| 26 (36.6%)                                      |
| **p.value**                                     |
| 0.040                                           |
| **Telemedicine cohort: Smartphone application no used vs Used** |
| **Retrospective cohort (RC) vs Telemedicine cohort (TC)** |
| **p.value**                                     |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea index (events/h), Median [Q1; Q3]** |
| 46.0 [32.5;67.6]                                |
| 40.8 [26.8;57.5]                                |
| 6.897                                           |
| **TC noAPP**                                    |
| 36.8 [25.1;53.0]                                |
| 53.1 [31.5;71.1]                                |
| **Apnea/hipoapnea supine index (events/h), Median [Q1; Q3]** |
| 57.5 [39.2;72.4]                                |
| 53.6 [32.0;70.2]                                |
| 0.157                                           |
| **TC noAPP**                                    |
| 47.3 [28.9;66.3]                                |
| 58.5 [38.6;75.6]                                |
| **Apnea/hipoapnea index (events/h), Median [Q1; Q3]** |
| 22.4 (26.1)                                     |
| 19.0 (22.1)                                     |
| 0.356                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea supine index (events/h), Median [Q1; Q3]** |
| 4.00 (2.30;6.70)                                |
| 4.00 (2.30;6.70)                                |
| 0.006                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea index (events/h), Median [Q1; Q3]** |
| 4.10 [2.20;7.55]                                |
| 3.40 [2.58;4.62]                                |
| 0.424                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea supine index (events/h), Median [Q1; Q3]** |
| 7.69 (2.05)                                     |
| 9.02 (0.64)                                     |
| 0.001                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea supine index (events/h), Median [Q1; Q3]** |
| 9.00 (0.64)                                     |
| 9.06 (0.64)                                     |
| 0.380                                           |
| **CPAP TREATMENT**                              |
| CPAP adaptation, N (%)                         |
| 64 (90.1%)                                      |
| 111 (94.9%)                                     |
| 0.346                                           |
| **Telemedicine cohort: Smartphone application no used vs Used** |
| **Retrospective cohort (RC) vs Telemedicine cohort (TC)** |
| **p.value**                                     |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Epworth Sleepiness Scale at diagnosis, Mean (SD)** |
| 9.00 (0.64)                                     |
| 9.06 (0.64)                                     |
| 0.380                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Epworth Sleepiness Scale at diagnosis, Mean (SD)** |
| 7.69 (2.05)                                     |
| 9.02 (0.64)                                     |
| 0.001                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Epworth Sleepiness Scale at diagnosis, Mean (SD)** |
| 9.00 (0.64)                                     |
| 9.06 (0.64)                                     |
| 0.380                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Epworth Sleepiness Scale at diagnosis, Mean (SD)** |
| 7.69 (2.05)                                     |
| 9.02 (0.64)                                     |
| 0.001                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea supine index (events/h), Median [Q1; Q3]** |
| 9.00 (0.64)                                     |
| 9.06 (0.64)                                     |
| 0.380                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea supine index (events/h), Median [Q1; Q3]** |
| 7.69 (2.05)                                     |
| 9.02 (0.64)                                     |
| 0.001                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
| TC_noAPP                                        |
| TC_APP                                          |
| **Apnea/hipoapnea supine index (events/h), Median [Q1; Q3]** |
| 7.69 (2.05)                                     |
| 9.02 (0.64)                                     |
| 0.001                                           |
| **RC N=71**                                     |
| **TC N=117**                                    |
### A) RC - TC multivariate logistic model: CPAP adherence > 4 hours per night

| Predictors                                      | Univariate | Multivariate |
|-------------------------------------------------|------------|--------------|
|                                                 | Odds Ratios | std. Error | CI     | p   | Odds Ratios | std. Error | CI     | p   |
| (Intercept)                                     | 2.37        | 0.65        | 1.41 - 4.14 | **0.002** | 0.04 | 0.06 | 0.00 - 0.83 | **0.042** |
| Telemedicine vs Retrospective                   | 0.72        | 0.24        | 0.37 - 1.38 | 0.331 | 0.64 | 0.24 | 0.30 - 1.33 | 0.239 |
| Age                                             | 1.05        | 0.02        | 1.02 - 1.09 |     | 1.21 | 0.47 | 0.58 - 2.62 | 0.614 |
| Gender [Female]                                 |             |             |         |     | 1.02 | 0.02 | 0.97 - 1.07 | 0.517 |
| BMI                                             |             |             |         |     | 1.60 | 0.70 | 0.85 - 3.94 | 0.134 |
| Educational level [High School and Associated degree OR College and Graduate degree] | 1.00        | 0.01        | 0.98 - 1.01 | 0.731 | 1.05 | 0.04 | 0.98 - 1.12 | 0.152 |
| Apnea hipoapnea index (events per hour)         |             |             |         |     | 1.01 | 0.03 | 1.05 - 1.16 | <0.001 |
| Epworth sleepiness scale at diagnosis           |             |             |         |     | 1.05 | 0.04 | 0.98 - 1.15 | 0.148 |

**Observations**: 175, **R2 Tjur**: 0.005, **AIC**: 228.062

### B) TC_noAPP – TC_APP used multivariate logistic model: CPAP adherence > 4 hours per night

| Predictors                                      | Univariate | Multivariate |
|-------------------------------------------------|------------|--------------|
|                                                 | Odds Ratios | std. Error | CI     | p   | Odds Ratios | std. Error | CI     | p   |
| (Intercept)                                     | 1.42        | 0.33        | 0.90 - 2.27 | 0.135 | 0.00 | 0.00     | 0.00 - 0.01 | **0.001** |
| APP used vs No-APP used                         | 1.83        | 0.81        | 0.79 - 4.49 | 0.169 | 2.09 | 1.12     | 0.75 - 6.23 | 0.169 |
| Age                                             | 1.10        | 0.03        | 1.05 - 1.16 |     | 0.97 | 0.50     | 0.35 - 2.74 | 0.956 |
| Gender [Female]                                 |             |             |         |     | 1.06 | 0.04     | 0.98 - 1.15 | 0.148 |
| BMI                                             |             |             |         |     | 3.94 | 2.28     | 1.33 - 13.04 | **0.017** |
| Educational level [High School and Associated degree OR College and Graduate degree] | 1.02        | 0.01        | 1.00 - 1.04 | 0.132 | 1.05 | 0.05     | 0.96 - 1.15 | 0.289 |
| Apnea hipoapnea index (events per hour)         |             |             |         |     | 1.02 | 0.01     | 1.00 - 1.04 | 0.132 |
| Epworth sleepiness scale at diagnosis           |             |             |         |     | 1.05 | 0.05     | 0.96 - 1.15 | 0.289 |

**Observations**: 111, **R2 Tjur**: 0.017, **AIC**: 148.248

**R2 Tjur**: 0.005, **AIC**: 207.984

---

**Table 3. Multivariate logistic models**

**A)** RC - TC multivariate logistic model: CPAP adherence > 4 hours per night

**B)** TC_noAPP – TC_APP used multivariate logistic model: CPAP adherence > 4 hours per night

---

**Multivariate Models**

- **Odds Ratios**: The odds of the event occurring relative to the baseline
- **std. Error**: Standard error of the odds ratio
- **CI**: Confidence Interval
- **p**: p-value, indicating statistical significance

---

**Note**: Table entries and calculations are presented to demonstrate the use of logistic regression models for CPAP adherence analysis.
### RC - TC multivariate linear model: Patient satisfaction

| Predictors                                         | Univariate | Multivariate 1 | Multivariate 2 |
|----------------------------------------------------|------------|----------------|---------------|
|                                                    | Estimates  | std. Error     | CI            | Estimates  | std. Error | CI            | Estimates  | std. Error | CI            | p  |
| (Intercept)                                        | 7.69       | 0.17           | 7.35 – 8.02   | <0.00       | 7.64       | 0.18          | 7.29 – 7.99 | <0.00       | 7.63       | 0.22          | 7.19 – 8.07 | 1  |
| Telemedicine vs Retrospective                      | 1.33       | 0.21           | 0.91 – 1.75   | <0.00       | 1.38       | 0.22          | 0.94 – 1.82 | <0.00       | 1.40       | 0.23          | 0.94 – 1.85 | 1  |
| Age                                                | 0.04       | 0.11           | -0.18 – 0.25  | 0.745       | 0.03       | 0.12          | -0.20 – 0.26 | 0.794       | 0.09       | 0.12          | -0.15 – 0.32 | 0.463 |
| BMI                                                | 0.10       | 0.11           | -0.12 – 0.32  | 0.364       | 0.09       | 0.12          | -0.15 – 0.32 | 0.463       | -0.13      | 0.11          | -0.34 – 0.09 | 0.248 |
| Apnea hipoapnea index (events per hour)            | -0.12      | 0.11           | -0.33 – 0.09  | 0.242       | -0.13      | 0.11          | -0.34 – 0.09 | 0.248       | 0.24       | 0.11          | 0.02 – 0.45 | 0.029 |
| Epworth sleepiness scale at diagnosis              | 0.24       | 0.11           | 0.02 – 0.45   | 0.030       | 0.24       | 0.11          | 0.02 – 0.45 | 0.030       | 0.02       | 0.23          | -0.45 – 0.47 | 0.967 |
| Gender [Female]                                    |            |                |               |            |            |               |              |            |            |               |    |
| Educational level [High School and Associated degree OR College and Graduate degree] |            |                |               |            |            |               |              |            |            |               |    |
| Observations                                       | 170        |                |               | 160        |                |               |              | 157        |                |               |    |
| R2 / R2 adjusted                                   | 0.185      |                |               | 0.227 / 0.202 |                |               |              | 0.232 / 0.196 |                |    |
| AIC                                                | 582.165    |                |               | 553.937    |                |               |              | 157        |                |               |    |
Table 4 - Patients’ survey on CPAP adaptation and follow-up

|                                | Retrospective cohort (RC) vs Telemedicine cohort (TC) | Telemedicine cohort: TC-noAPP vs TC-APP |
|--------------------------------|-----------------------------------------------------|----------------------------------------|
|                                | RC (N=61) | TC (N=102) | p.value | TC-noAPP (N=69) | TC-APP (N=33) | p.value |
| Satisfaction with the follow up, N (%): |            |            |         |                |                |         |
| No                              | 9 (14.8%) | 0 (0.00%)  | <0.001  | 0 (0.00%)       | 0 (0.00%)      | 0.103   |
| Partially                       | 10 (16.4%)| 2 (1.96%)  |         | 0 (0.00%)       | 2 (6.06%)      |         |
| Yes                             | 42 (68.9%)| 100 (98.0%)|         | 69 (100%)       | 31 (93.9%)     |         |
| Easy access to healthcare professionals, N (%): |            |            |         |                |                |         |
| No                              | 12 (19.7%)| 0 (0.00%)  | <0.001  | 0 (0.00%)       | 0 (0.00%)      |         |
| Partially                       | 13 (21.3%)| 0 (0.00%)  |         | 0 (0.00%)       | 0 (0.00%)      |         |
| Yes                             | 36 (59.0%)| 102 (100%) |         | 69 (100%)       | 33 (100%)      |         |
| Confidence in the confidentiality of the data, N (%): |            |            | 0.018   |                |                |         |
| No                              | 1 (1.64%) | 0 (0.00%)  |         | 0 (0.00%)       | 0 (0.00%)      |         |
| Partially                       | 3 (4.92%) | 0 (0.00%)  |         | 0 (0.00%)       | 0 (0.00%)      |         |
| Yes                             | 57 (93.4%)| 102 (100%) |         | 69 (100%)       | 33 (100%)      |         |
| Rather be followed telematically or in person (the opposite group), N (%): |            |            | <0.001  |                |                | 1.000   |
| No                              | 25 (41.0%)| 96 (94.1%) |         | 65 (94.2%)      | 31 (93.9%)     |         |
| Partially                       | 14 (23.0%)| 0 (0.00%)  |         | 0 (0.00%)       | 0 (0.00%)      |         |
| Yes                             | 22 (36.1%)| 6 (5.88%)  |         | 4 (5.80%)       | 2 (6.06%)      |         |
| Increase in number of hours of CPAP because of the follow up done, N (%): |            |            | 0.063   | 0.011           |                |         |
| No                              | 19 (31.1%)| 50 (49.0%) |         | 38 (55.1%)      | 12 (36.4%)     |         |
| Partially                       | 15 (24.6%)| 15 (14.7%) |         | 5 (7.25%)       | 10 (30.3%)     |         |
| Yes                             | 27 (44.3%)| 37 (36.3%) |         | 26 (37.7%)      | 11 (33.3%)     |         |
| Use of the telemedicine and telemonitoring system again or recommendation of it to others, N (%): |            |            |         |                |                | 0.390   |
| No                              | 0 (0.%)   | 2 (1.96%)  |         | 1 (1.45%)       | 1 (3.03%)      |         |
| Partially                       | 0 (0.%)   | 2 (1.96%)  |         | 1 (1.45%)       | 1 (3.03%)      |         |
| Yes                             | 0 (0.%)   | 98 (96.1%) |         | 67 (97.1%)      | 31 (93.9%)     |         |
### Table 5 - APP server data (TC-APP)

| Category                                              | N   | Percentage |
|-------------------------------------------------------|-----|------------|
| **Messages sent, N (%):**                              |     |            |
| No                                                    | 14  | 38.9%      |
| Yes                                                   | 22  | 61.1%      |
| **Follow up questionnaires, N (%):**                   |     |            |
| No                                                    | 11  | 34.4%      |
| Yes                                                   | 21  | 65.6%      |
| **Message initiation through the app, N (%):**         |     |            |
| No messages                                           | 0   | 0%         |
| Patient                                               | 16  | 72.7%      |
| Sleep Unit Staff                                      | 6   | 27.3%      |
| Number of medical messages, Median [25% ; 75%]        | 2.5 | [1 ; 5.75] |
| **Message subject, N (%):**                           |     |            |
| Greeting                                              | 1   | 4.6%       |
| Adverse effect                                        | 15  | 68.2%      |
| General question CPAP                                  | 2   | 9.1%       |
| Question from the staff about an alert message         | 4   | 18.2%      |
| **Messages resulted in action to improve CPAP adaptation, N (%):** |     |            |
| No                                                    | 12  | 57.1%      |
| Yes                                                   | 9   | 42.9%      |
| **Nasal congestion or obstruction when using CPAP, N (%):** |     |            |
| No                                                    | 7   | 63.6%      |
| Yes                                                   | 3   | 27.3%      |
| Does not know                                         | 1   | 9.1%       |
| **Air leaks with the use of CPAP, N (%):**             |     |            |
| No                                                    | 9   | 81.8%      |
| Yes                                                   | 2   | 18.2%      |
| Does not know                                         | 0   | 0%         |
| **Skin marks or irritation with CPAP use, N (%):**     |     |            |
| No                                                    | 7   | 63.6%      |
| Yes                                                   | 4   | 36.4%      |
| Does not know                                         | 0   | 0%         |
| **Dry mouth with CPAP use, N (%):**                    |     |            |
| No                                                    | 6   | 54.6%      |
| Yes                                                   | 5   | 45.5%      |
| Does not know                                         | 0   | 0%         |
| **Excessive air pressure with the use of CPAP, N (%):** |     |            |
| No                                                    | 8   | 80%        |
| Yes                                                   | 2   | 20%        |
| Does not know                                         | 0   | 0%         |
| **Chest or abdominal discomfort with CPAP use, N (%):** |     |            |
| No                                                    | 7   | 70%        |
| Yes                                                   | 3   | 30%        |
| Does not know                                         | 0   | 0%         |
| **Sleeping hours using CPAP, Mean (standard deviation)** |     |            |
|                                                        | 6.36| (1.21)     |
Figure 1. Flowchart